ABSTRACT
Although screening of prenatal congenital heart disease (CHD) has improved over the last decade, the diagnosis rate can still be as low as 40%. The axial 4 chamber (A4C) is the most reliably obtained cardiac view in the fetal screening ultrasound but alone only has a maximum clinical sensitivity of 50-60%, particularly in large multicenter studies in low-risk populations. Standard biometrics, like cardiac axis (CA), cardiothoracic ratio (CTR) and cardiac chamber fractional area change (FAC), have individually been shown to be useful for CHD screening and can all be obtained from A4C alone. However, these biometrics are vastly underutilized because they are time-consuming to extract and difficult to interpret all at once. We hypothesized that using six standard biometrics in combination can improve complex CHD screening versus any one biometric alone. K-means clustering was performed to segregate the patterns of heart measurements into clusters. Sensitivity and specificity for CHD was 87% and 75%, respectively. Here, we demonstrate that a composite of six standard biometric has better sensitivity and accuracy for CHD than any one biometric alone and better than A4C visual assessment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the National Institutes of Health and the Department of Defense, both to R.A.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board of the University of California, San Francisco
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Due to the vulnerable status of the patient population and waived consent, data will not be made available.
